Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCEFAZOLIN SODIUM (cefazolin) by Novartis is clinical pharmacology studies have shown that following intravenous administration of cefazolin for injection to normal volunteers, mean serum concentrations peaked at approximately 185 mcg/ml and were approximately 4 mcg/ml at 8 hours for a 1-gram dose. Approved for the treatment of the following infections due to susceptible organisms: respiratory tract infections: due to s, development of drug-resistant bacteria, maintain the effectiveness of cefazolin for injection and 4 more indications. First approved in 1988.
Drug data last refreshed 22h ago
CLINICAL PHARMACOLOGY Studies have shown that following intravenous administration of cefazolin for injection to normal volunteers, mean serum concentrations peaked at approximately 185 mcg/mL and were approximately 4 mcg/mL at 8 hours for a 1-gram dose. The serum half-life for cefazolin is…
Worked on CEFAZOLIN SODIUM at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
Cefazolin PK Study 3g vs 2g
Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients
An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo